Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 16:42:108271.
doi: 10.1016/j.dib.2022.108271. eCollection 2022 Jun.

Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis

Hristos Karakizlis  1 , Christian Nahrgang  1 , Kevin Strecker  2 , Jiangping Chen  1 , Mostafa Aly  3   4 , Heiko Slanina  5 , Christian G Schüttler  5 , Isla Esso  1 , Martin Wolter  1 , Darina Todorova  1 , Sönke Jessen  1 , Andrea Adamik  1 , Claudio Ronco  6   7 , Werner Seeger  1   8   9 , Rolf Weimer  1 , Martina Sester  10 , Horst-Walter Birk  1 , Faeq Husain-Syed  1   6
Affiliations

Data on immunogenicity and reactogenicity to COVID-19 vaccination among patients receiving maintenance dialysis

Hristos Karakizlis et al. Data Brief. .

Abstract

Compared with the general population, patients receiving maintenance dialysis are at increased risk for morbidity and mortality associated with coronavirus disease 2019 (COVID-19). Currently, data on severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)-specific immunity post-vaccination in patients on maintenance dialysis are scarce given that the effectiveness of the vaccines has not been explicitly tested in this population due to their common exclusion from SARS-CoV-2 vaccination trials. We herein present data of the specific cellular (interferon-γ and interleukin-2 ELISpot assays) and humoral immune responses (dot plot array and chemiluminescent microparticle immunoassay) at 4 weeks and 6 weeks following a single dose or a complete homologous dual dose SARS-CoV-2 vaccine regimen in 60 adult patients on maintenance dialysis (six with a history of COVID-19). The data was produced in a framework of a project focused on a) quantifying the immune response after full vaccination, b) evaluating the short-term durability of immune response, and c) examining the reactogenicity of SARS-CoV-2 vaccine regimens in patients on maintenance dialysis.

Keywords: Cellular immune response; Hemodialysis; Immunoglobulins; Peritoneal dialysis; SARS-CoV-2; T cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kevin Strecker is employee of AID/GenID, the manufacturer of the ELISpot assay. None of the other authors declare any competing interests.

Figures

Fig. 1
Fig. 1
SARS-CoV-2-specific T-cell responses using a multicolor FluoroSpot Immune assay.
See this image and copyright information in PMC

References

    1. De Meester J., De Bacquer D., Naesens M., Meijers B., Couttenye M.M. Incidence, characteristics, and outcome of COVID-19 in adults on kidney replacement therapy: a regionwide registry study. J. Am. Soc. Nephrol. 2021 doi: 10.1681/ASN.2020060875. - DOI - PMC - PubMed
    1. J Jager K.J., Kramer A., Chesnaye N.C., Couchoud C., Sánchez-Álvarez J.E., Garneata L., Collart F., Hemmelder M.H., Ambühl P., Kerschbaum J., Legeai C., Del Pino Y Pino M.D., Mircescu G., Mazzoleni L., Hoekstra T., Winzeler R., Mayer G., Stel V.S., Wanner C., Zoccali C., Massy Z.A. Results from the ERA-EDTA registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe. Kidney Int. 2020 doi: 10.1016/j.kint.2020.09.006. - DOI - PMC - PubMed
    1. El Karoui K., De Vriese A.S. COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment. Kidney Int. 2022 doi: 10.1016/j.kint.2022.01.022. - DOI - PMC - PubMed
    1. Karakizlis H., Nahrgang C., Strecker K., Chen J., Aly M., Slanina H., Schüttler C.G., Esso I., Wolter M., Todorova D., Jessen S., Adamik A., Ronco C., Seeger W., Weimer R., Sester M., Birk H.W., Husain-Syed F. Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clin. Immunol. 2022 doi: 10.1016/j.clim.2022.108961. - DOI - PMC - PubMed
    1. Favà A., Donadeu L., Sabé N., Pernin V., González-Costello J., Lladó L., Meneghini M., Charmetant X., García-Romero E., Cachero A., Torija A., Rodriguez-Urquia R., Crespo E., Teubel I., Melilli E., Montero N., Manonelles A., Preyer R., Strecker K., Ovize A., Lozano J.J., Sidorova J., Cruzado J.M., Le Quintrec M., Thaunat O., Bestard O. SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. Am. J. Transplant. 2021 doi: 10.1111/ajt.16570. - DOI - PMC - PubMed

LinkOut - more resources